Metabolic Effects of Signal Transduction Inhibition in Cancer Assessed by Magnetic Resonance Spectroscopy

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2011 May 4

PMID 21536506

Citations 6

Authors

Siver Andreas Moestue

Olav Engebraaten

Ingrid Susann Gribbestad

Affiliations

Soon will be listed here.

Abstract

Despite huge efforts in development of drugs targeting oncogenic signalling, the number of such drugs entering clinical practice to date remains limited. Rational use of biomarkers for drug candidate selection and early monitoring of response to therapy may accelerate this process. Magnetic resonance spectroscopy (MRS) can be used to assess metabolic effects of drug treatment both in vivo and in vitro, and technological advances are continuously increasing the utility of this non-invasive method. In this review, we summarise the use of MRS for monitoring the effect of targeted anticancer drugs, and discuss the potential role of MRS in the context of personalised cancer treatment.

Citing Articles

Targeting the Warburg Effect in Cancer: Where Do We Stand?.

Barba I, Carrillo-Bosch L, Seoane J Int J Mol Sci. 2024; 25(6).

PMID: 38542116 PMC: 10970388. DOI: 10.3390/ijms25063142.

Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma.

Al-Saffar N, Troy H, Wong Te Fong A, Paravati R, Jackson L, Gowan S Br J Cancer. 2018; 119(9):1118-1128.

PMID: 30377337 PMC: 6219501. DOI: 10.1038/s41416-018-0242-3.

Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents.

Serkova N, Eckhardt S Front Oncol. 2016; 6:152.

PMID: 27471678 PMC: 4946377. DOI: 10.3389/fonc.2016.00152.

Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics.

Josephs D, Sarker D Transl Oncogenomics. 2016; 7(Suppl 1):33-49.

PMID: 26917948 PMC: 4762492. DOI: 10.4137/TOG.S30529.

Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer.

Moestue S, Dam C, Gorad S, Kristian A, Bofin A, Maelandsmo G Breast Cancer Res. 2013; 15(1):R16.

PMID: 23448424 PMC: 3672699. DOI: 10.1186/bcr3391.

References

McLarty K, Fasih A, Scollard D, Done S, Vines D, Green D . 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice. J Nucl Med. 2009; 50(11):1848-56. DOI: 10.2967/jnumed.109.067231. View

Schwartz D, Bankson J, Lemos Jr R, Lai S, Thittai A, He Y . Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther. 2010; 9(7):2057-67. PMC: 2935253. DOI: 10.1158/1535-7163.MCT-09-0768. View

Dang C, Le A, Gao P . MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009; 15(21):6479-83. PMC: 2783410. DOI: 10.1158/1078-0432.CCR-09-0889. View

Gabellieri C, Reynolds S, Lavie A, Payne G, Leach M, Eykyn T . Therapeutic target metabolism observed using hyperpolarized 15N choline. J Am Chem Soc. 2008; 130(14):4598-9. DOI: 10.1021/ja8001293. View

Singh D, Banerji A, Dwarakanath B, Tripathi R, Gupta J, Mathew T . Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol. 2005; 181(8):507-14. DOI: 10.1007/s00066-005-1320-z. View

Milkevitch M, Shim H, Pilatus U, Pickup S, Wehrle J, Samid D . Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells. Biochim Biophys Acta. 2005; 1734(1):1-12. DOI: 10.1016/j.bbalip.2005.01.008. View

Anthony M, Zhao M, Brindle K . Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells. J Biol Chem. 1999; 274(28):19686-92. DOI: 10.1074/jbc.274.28.19686. View

Matoba S, Kang J, Patino W, Wragg A, Boehm M, Gavrilova O . p53 regulates mitochondrial respiration. Science. 2006; 312(5780):1650-3. DOI: 10.1126/science.1126863. View

Keshari K, Wilson D, Chen A, Bok R, Larson P, Hu S . Hyperpolarized [2-13C]-fructose: a hemiketal DNP substrate for in vivo metabolic imaging. J Am Chem Soc. 2009; 131(48):17591-6. PMC: 2796621. DOI: 10.1021/ja9049355. View

10.

Moestue S, Engebraaten O, Gribbestad I . Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy. Mol Oncol. 2011; 5(3):224-41. PMC: 5528296. DOI: 10.1016/j.molonc.2011.04.001. View

11.

Sergina N, Moasser M . The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 2007; 13(12):527-34. PMC: 3035105. DOI: 10.1016/j.molmed.2007.10.002. View

12.

Mertens K, Slaets D, Lambert B, Acou M, de Vos F, Goethals I . PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Mol Imaging. 2010; 37(11):2188-93. DOI: 10.1007/s00259-010-1496-z. View

13.

Beloueche-Babari M, Jackson L, Al-Saffar N, Eccles S, Raynaud F, Workman P . Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol Cancer Ther. 2006; 5(1):187-96. DOI: 10.1158/1535-7163.MCT-03-0220. View

14.

Prior J, Montemurro M, Orcurto M, Michielin O, Luthi F, Benhattar J . Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2008; 27(3):439-45. DOI: 10.1200/JCO.2008.17.2742. View

15.

Ramirez de Molina A, Rodriguez-Gonzalez A, Lacal J . From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design. Cancer Lett. 2004; 206(2):137-48. DOI: 10.1016/j.canlet.2003.08.031. View

16.

Loeb L, Loeb K, Anderson J . Multiple mutations and cancer. Proc Natl Acad Sci U S A. 2003; 100(3):776-81. PMC: 298677. DOI: 10.1073/pnas.0334858100. View

17.

Beloueche-Babari M, Jackson L, Al-Saffar N, Workman P, Leach M, Ronen S . Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res. 2005; 65(8):3356-63. DOI: 10.1158/10.1158/0008-5472.CAN-03-2981. View

18.

Rosbe K, Brann T, Holden S, Teicher B, Frei 3rd E . Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother Pharmacol. 1989; 25(1):32-6. DOI: 10.1007/BF00694335. View

19.

Kharas M, Deane J, Wong S, OBosky K, Rosenberg N, Witte O . Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood. 2004; 103(11):4268-75. DOI: 10.1182/blood-2003-07-2193. View

20.

Brandes A, Ward C, Ronen S . 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2. Breast Cancer Res. 2010; 12(5):R84. PMC: 3096977. DOI: 10.1186/bcr2729. View